Owen Sharp, our Chief Executive, blogs on the recent headlines regarding the Cancer Drugs Fund and prostate cancer drug Jevtana.
Over the last few days, the media have been going to town with coverage of the Cancer Drugs Fund (CDF) and a decision by NHS England to stop funding some of the drugs on its list. You’ve probably seen some of the headlines.
If you’re taking a drug that’s funded by the CDF the most important take home message is that your treatment will continue for as long as your doctor thinks you need it, regardless of the announcement NHS England makes on Monday.
We found out late last year that Jevtana (cabazitaxel) was one of the drugs the CDF was considering dropping from the list, but we won’t know the official decision about it, or the reasons for no longer funding it, until Monday. Nevertheless, as you can imagine, I’ve been following the process closely and we’ll update you as soon as we have all the facts.
NHS England’s need to remove funding for some cancer drugs is yet another example of a broken system that is denying men access to the vital drugs they need.
That’s why we’ve been working hard behind the scenes to push for an entire overhaul of the drug appraisal and funding system.
In fact, we’re now working on this with nine other cancer charities, and have a commitment from NICE, NHS England, the Association of the British Pharmaceutical Industry (ABPI) and the Department of Health to work with us to create a better process for getting cancer drugs to the people who need them.
It won’t happen tomorrow, but it will happen; we’ll fight tooth and nail to make sure of that.